These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 582755)

  • 41. Metabolism of a new cardiotonic agent, (-)-alpha-(3,4-dimethoxyphenethylaminomethyl)-4-hydroxybenzyl alcohol (TA-064), in man. O-demethylation and ring hydroxylation.
    Suzuki T; Hashimura Y; Takeyama S
    Drug Metab Dispos; 1983; 11(4):377-86. PubMed ID: 6137347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a screening method for the most commonly abused anticholinergic drugs in Jordan; trihexyphenidyl, procyclidine and biperiden.
    Hadidi KA
    Leg Med (Tokyo); 2004 Oct; 6(4):233-41. PubMed ID: 15363448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New designer drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.
    Sauer C; Peters FT; Staack RF; Fritschi G; Maurer HH
    J Mass Spectrom; 2006 Aug; 41(8):1014-29. PubMed ID: 16817170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The biotransformation of the anticonvulsant 4-p-chlorophenylpyrrol-3-morpholino-2-carboxylic acid methyl ester (AWD 140-076)].
    Langner A; Rätzer J; Rickert H; Nerlich C; Franke P
    Pharmazie; 1993 Nov; 48(11):849-53. PubMed ID: 8295913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450.
    Bathelt CM; Ridder L; Mulholland AJ; Harvey JN
    Org Biomol Chem; 2004 Oct; 2(20):2998-3005. PubMed ID: 15480465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism and urinary excretion of benzhexol in humans.
    Nation RL; Triggs EJ; Vine J
    Xenobiotica; 1978 Mar; 8(3):165-9. PubMed ID: 654310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans.
    Nakashima E; Yokogawa K; Ichimura F; Kurata K; Kido H; Yamaguchi N; Yamana T
    Chem Pharm Bull (Tokyo); 1987 Feb; 35(2):718-25. PubMed ID: 3594682
    [No Abstract]   [Full Text] [Related]  

  • 49. [CLINICAL EXPERIENCES WITH DEPOT FORMS OF ANTI-PARKINSON DRUGS (AKINETON AND KR 339 KNOLL)].
    UMBACH W
    Med Welt; 1963 Aug; 33():1634-7. PubMed ID: 14045620
    [No Abstract]   [Full Text] [Related]  

  • 50. Simultaneous microdetermination of biperiden, haloperidol, and trihexyphenidyl in plasma and its application to pharmacokinetic analysis after concomitant intravenous administration of the drugs to rabbits.
    Yokogawa K; Nakashima E; Ichimura F; Yamana T
    Chem Pharm Bull (Tokyo); 1985 Oct; 33(10):4581-6. PubMed ID: 4092273
    [No Abstract]   [Full Text] [Related]  

  • 51. [Absorption, distribution and excretion of 14 C-labelled 6,6,9-trimethyl-9-azabicyclo(3,3,1)non-3 -yl a,a-di(2-thienyl)glycolate hydrochloride monohydrate (PG-501)].
    Otsuka M; Nakamura S; Sato Y
    Yakugaku Zasshi; 1972 Aug; 92(8):986-96. PubMed ID: 4674420
    [No Abstract]   [Full Text] [Related]  

  • 52. [Antiparkinson agents].
    van der Kuy A; van der Bemd AA; Beysens AJ
    Tijdschr Ziekenverpl; 1977 Apr; 30(8):377-8. PubMed ID: 585506
    [No Abstract]   [Full Text] [Related]  

  • 53. Aromatic hydroxylation as an analytical reaction.
    Connors KA; Albert KS
    Anal Chem; 1972 Apr; 44(4):879-81. PubMed ID: 22309566
    [No Abstract]   [Full Text] [Related]  

  • 54. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results.
    Delvaux M; Wingate D
    J Int Med Res; 1997; 25(5):225-46. PubMed ID: 9364286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biperiden effects and plasma levels in volunteers.
    Hollmann M; Brode E; Greger G; Müller-Peltzer H; Wetzelsberger N
    Eur J Clin Pharmacol; 1984; 27(5):619-21. PubMed ID: 6519170
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.
    Grimaldi R; Perucca E; Ruberto G; Gelmi C; Trimarchi F; Hollmann M; Crema A
    Eur J Clin Pharmacol; 1986; 29(6):735-7. PubMed ID: 3709619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical pharmacokinetics of anti-parkinsonian drugs.
    Cedarbaum JM
    Clin Pharmacokinet; 1987 Sep; 13(3):141-78. PubMed ID: 3311529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Metabolism of antiparkinson drugs. An example of competitive hydroxylation].
    Stock B; Spiteller G
    Arzneimittelforschung; 1979; 29(4):610-5. PubMed ID: 582755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differentiation between isomeric oxidative metabolites of a piperidine-containing drug by liquid chromatography-tandem mass spectrometry with stable-isotope tracer technique.
    Kato K; Jingu S; Ogawa N; Higuchi S
    Biomed Chromatogr; 2002 Feb; 16(1):25-30. PubMed ID: 11816008
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-human serum albumin binding studied by capillary electrophoresis with electrochemiluminescence detection.
    Zhao X; You T; Liu J; Sun X; Yan J; Yang X; Wang E
    Electrophoresis; 2004 Oct; 25(20):3422-6. PubMed ID: 15490448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.